EN DE
Watch Proteomics International Laboratories Ltd for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Proteomics International Laboratories Ltd (PIQ) fair value: what the stock is really worth

As of Nov 9, 2026: fair value (intrinsic value) of Proteomics International Laboratories Ltd stock A$0.02, price A$0.10, that is 75.3% below the price, quality 37 out of 100. Rating: strongly overvalued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare AU · ISIN AU000000PIQ0

PI Proteomics International Laboratories Ltd logo Thin data Nov 4, 2026

Proteomics International Laboratories Ltd

PIQ · AU
Very expensive, weak quality

Our calculation puts a fair price 75% below what the stock costs today.

Low debt
Fair value A$0.0238 · Strongly overvalued
Quality 37/100
Weak Growth (revenue 5y −26.7 %/yr in AUD)
Negative free cash flow
Trails peers (3/9)
Narrow moat 10/100 · thin data
Thin data
Watch Proteomics International Laboratories Ltd for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

A$1.34 A$0.0910 Fair Value A$0.0238 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 4, 2026.

How to read this chart

60‑month range A$0.0910 – A$1.34 · fair‑value band A$0.0143 – A$0.0238 · the A$0.0960 price screens above the A$0.0238 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 4, 2026.

Follow Proteomics International Laboratories in your weekly email

Every Wednesday you see whether Proteomics International Laboratories is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Proteomics International Laboratories Ltd operates as a medical technology company with a focus on the area of proteomics in Australia, New Zealand, the United States, Europe, India, and Southeast Asia.

Show moreShow less

It provides PromarkerD, a blood test to predict diabetic kidney disease (DKD). The company's products under development include PromarkerEndo, which has completed clinical validation phase for endometriosis diagnosis; PromarkerEso, which has completed clinical validation trials for esophageal cancer diagnosis; and OxiDx (2-tag), which has completed clinical validation phase for oxidative stress treatment.

It is also developing diagnostic tests for that includes DKD - T1D, that is under clinical phase for type 1 diabetes, diabetic retinopathy, and diabetic neuropathy; Asthma and COPD, which has completed proof-of-concept study trials for asthma and chronic obstructive pulmonary disease; Plant Dieback, that is under development phase for phytophthora dieback; Diabetic Retinopathy, which has completed discovery phase for sight-threatening retinopathy; and Diabetic Neuropathy, that is under research phase to investigate predictive biomarkers for diabetic neuropathy.

The company also offers analytical services, such as specialist contract research focusing on biomarker discovery, biosimilars quality control, and pharmacokinetic testing for clinical trials.

It has strategic collaboration with Harry Perkins Institute of Medical Research, Bioplatforms Australia, The University of Western Australia, Australian Research Council Training Centre, and the Australian Centre.

Proteomics International Laboratories Ltd was founded in 2001 and is based in Perth, Australia.

Stock analysis

Proteomics International Laboratories Ltd (PIQ) currently trades at A$0.0960, while our model-based Fair Value estimate is A$0.0238, 75% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 92/100, which puts the data coverage at low.

Scenario range: A$0.0143 (bear) to A$0.0238 (bull), the price of A$0.0960 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 37/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

Proteomics International Laboratories Ltd reported revenue of A$278K in FY2026 versus A$1.5M in FY2022, a compound −34.3%/yr. Reported net income was −A$8.6M in FY2026.

Key figures

Market cap A$15.9M (≈ $10.9M) Micro · P/S ratio 5.77 · EPS (TTM) A$−0.0600 · Return on equity −93.0% · Return on assets (EBIT) −89.0% (5-year average) · Operating margin −104% · Revenue growth (YoY) +6.7% · Free cash flow −A$7.9M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 10 out of 100 (low confidence).

What moves the price

The share trades about 89% below its 52-week high and 5% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −75%, PIQ screens richer than that median.

Fair Value models

Bear A$0.0143 Fair Value A$0.0238 Bull A$0.0238
Price A$0.0960 · Downside -75.3%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
NCAV (Graham) A$0.0100 A$0.0200 A$0.0200 55
All 1 models by family
Asset-Based
NCAV (Graham) A$0.0100 A$0.0200 A$0.0200 55

Open the full fair value analysis →

Quality Score breakdown

Overall quality 37/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 7
Are margins and returns getting better?
Cashflow 4
Do the profits arrive as real cash?
Financial strength 74
Debt, balance sheet and risk of trouble
Investment 67
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 1
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 0
Distance to the 52-week high, does not count
New shares 90
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−71.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−27.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−26.7%
Start year 2021 (pandemic). Over 10 years: −10.2% a year
Revenue growth 14 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−5.3%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−235.2% (2021) → −4,275.7% (2026)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2026 is a loss year, no rate is defined from a loss
not computed

PIQ screens overvalued: fair value 75% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Proteomics International Laboratories Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 558 stocks

Beats the industry median on 2/7 measures
Overall it trails its industry peers.
Valuation
Quality Score 37 · Below median
Fair Value upside −75.2% · Bottom 25%
Profitability
Return on assets −96.4% · Bottom 25%
Operating margin (12 months) −104.0% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 6.7% · Above median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 2.73× · Pricier than median
P/S (12 months) 4.71× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)34 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)100 · sector 97
DIVIDEND (yield)0 · sector 22

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Incyte Corporation INCY $119.65 $199.23 +67% vs PIQ
Regeneron Pharmaceuticals, Inc REGN $904.35 $1,275 +41% vs PIQ
Vertex Pharmaceuticals Incorporated VRTX $547.09 $601.80 +10% vs PIQ
Samsung Biologics Co 207940 1,516,000 KRW 1,667,600 KRW +10% vs PIQ
Genmab A/S GMAB kr 3,527 kr 3,880 +10% vs PIQ
WuXi Biologics (Cayman) Inc 2269 HK$47.62 HK$52.38 +10% vs PIQ
argenx SE ARGX $927.21 $908.40 −2% vs PIQ
CSL Limited CSL A$200.77 A$183.04 −9% vs PIQ
Celltrion, Inc 068270 211,000 KRW 74,945 KRW −64% vs PIQ
Royalty Pharma plc RPRX $67.30 $19.01 −72% vs PIQ

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Proteomics International Laboratories Ltd: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Proteomics International Laboratories Ltd Fair Value". https://www.fairvalue-calculator.com/stock/PIQ

Frequently asked questions

Is Proteomics International Laboratories Ltd (PIQ) overvalued or undervalued?
As of Nov 4, 2026, our model estimates a fair value of A$0.0238 versus a price of A$0.0960, about 75% lower (overvalued).
What is the fair value of PIQ?
Our model-based fair value for Proteomics International Laboratories Ltd is A$0.0238 (as of Nov 4, 2026), built from audited fundamentals. The current price: A$0.0960.
What is the quality score of PIQ?
Proteomics International Laboratories Ltd has a Quality Score of 37/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Proteomics International Laboratories Ltd (PIQ)?
Our model-based price target is the fair value of A$0.0238 (as of Nov 4, 2026) from 1 valuation models. Cautious scenario A$0.0143, optimistic scenario A$0.0238. It is a calculation from audited fundamentals, not an analyst target.
What is the Proteomics International Laboratories Ltd stock forecast for 2026?
Our models put fair value at A$0.0238, about 75% lower versus a price of A$0.0960 (overvalued). Cautious scenario A$0.0143, optimistic scenario A$0.0238. The calculation is refreshed regularly with new filings.
What is the intrinsic value of Proteomics International Laboratories Ltd (PIQ)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Proteomics International Laboratories Ltd it is A$0.0238 per share (as of Nov 4, 2026), against a price of A$0.0960. It is the blended result of 1 valuation models in 1 family (Asset-Based).
Is Proteomics International Laboratories Ltd stock overvalued or undervalued in 2026?
As of Nov 4, 2026, PIQ trades above its calculated fair value: price A$0.0960, fair value A$0.0238, a gap of about −75% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of PIQ?
No. The price is what the market pays today (A$0.0960); the fair value is what the company's own numbers justify (A$0.0238). For Proteomics International Laboratories Ltd the two are A$0.0723 per share apart. That gap is exactly why we show both numbers side by side.
How much is Proteomics International Laboratories Ltd worth?
The market values Proteomics International Laboratories Ltd at about A$15.9M (market capitalisation, as of Nov 4, 2026). Per share that is A$0.0960; our models calculate a fair value of A$0.0238 per share.
What do the bullish and bearish scenarios say about PIQ?
Our models span a range for Proteomics International Laboratories Ltd: cautious scenario A$0.0143, base A$0.0238, optimistic A$0.0238 per share (as of Nov 4, 2026, price A$0.0960). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Proteomics International Laboratories Ltd (PIQ)?
Balance-sheet figures for Proteomics International Laboratories Ltd (as of Nov 4, 2026): return on equity −93.0%. They feed the Quality Score of 37/100, which measures business quality independently of the share price.
How far is PIQ from its 52-week high?
Proteomics International Laboratories Ltd trades at A$0.0960, about 89% below its 52-week high of A$0.8400 and 5% above the low of A$0.0910 (as of Nov 9, 2026). Distance from the high says nothing about value: that is what the fair value of A$0.0238 is for.
Which stocks are comparable to Proteomics International Laboratories Ltd?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Proteomics International Laboratories Ltd stock attractive at the current price?
The data as of Nov 4, 2026: price A$0.0960, calculated fair value A$0.0238 (−75%), Quality Score 37/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of PIQ calculated?
We run Proteomics International Laboratories Ltd through 1 models from 1 family: Asset-Based. Every model gets the same audited fundamentals; the fair value of A$0.0238 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Proteomics International Laboratories Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Proteomics International Laboratories Ltd (PIQ)?
The closing price on Nov 9, 2026 was A$0.0960. Our model-based fair value is A$0.0238, about 75% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Proteomics International Laboratories Ltd right now?
The price sits above even our optimistic bull case (A$0.0238). The favourable scenario is already priced in. Weak quality (37/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of Proteomics International Laboratories Ltd

How large is the market capitalisation of Proteomics International Laboratories Ltd (PIQ)?
The market capitalisation of Proteomics International Laboratories Ltd is A$15.9M (≈ $10.9M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Proteomics International Laboratories Ltd (PIQ)?
The price-to-sales ratio of Proteomics International Laboratories Ltd is 5.77 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Proteomics International Laboratories Ltd (PIQ)?
Earnings per share at Proteomics International Laboratories Ltd are A$−0.0600. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Proteomics International Laboratories Ltd (PIQ)?
The return on equity (ROE) of Proteomics International Laboratories Ltd is −93.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Proteomics International Laboratories Ltd (PIQ)?
On an EBIT basis the return on assets of Proteomics International Laboratories Ltd is −89.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Proteomics International Laboratories Ltd (PIQ)?
The operating margin of Proteomics International Laboratories Ltd is −104% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Proteomics International Laboratories Ltd (PIQ)?
Revenue at Proteomics International Laboratories Ltd is growing +6.7% versus a year earlier (3y avg −27.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Proteomics International Laboratories Ltd (PIQ) generate?
The free cash flow of Proteomics International Laboratories Ltd is −A$7.9M (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Proteomics International Laboratories Ltd (PIQ) hold?
Proteomics International Laboratories Ltd holds more cash than debt, A$3.2M net (fiscal year 2026). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Proteomics International Laboratories Ltd in the live analysis

One click puts Proteomics International Laboratories Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.